U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07388563) titled 'Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma' on Feb. 04.
Brief Summary: Background:
T-cell lymphoma is a blood cancer that affects immune system cells. People tend to survive less than 1 year if this disease does not respond to treatment (is refractory) or comes back after treatment (relapses). Azacitidine and abatacept are 2 drugs that are used to treat other diseases. Researchers want to know if these drugs, used together, can help people with T-cell lymphoma.
Objective:
To learn if azacitidine combined with abatacept can shrink tumors in people with T-cell lymphoma.
Eligibility:
People aged 18 years an...